Study #2025-0656
A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HS-20110 in patients with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
HS-20110 (Phase Ia：Dose escalation ), HS-20110 (Phase Ib:Dose expansion )
Description
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumors
Study phase:
Phase I
Physician name:
Siqing Fu
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.